MENU

Vir Biotechnology: Elebsiran and Tobevibart Phase 2 SOLSTICE Data

Business Wire USA
Overview
Combination therapy with elebsiran and tobevibart achieved 100% undetectable viremia in patients completing 96 weeks of treatment for chronic hepatitis delta (CHD). Exploratory data suggests curative potential, with all ten patients who discontinued treatment achieving SVR12. These results support a planned global regulatory filing for the U.S. FDA in mid-2027.
In Depth

Key Findings

In the Phase 2 SOLSTICE trial, 100% (28/28) of patients who completed 96 weeks of monthly subcutaneous administration of elebsiran and tobevibart reached undetectable viremia. This deep virologic response was accompanied by improvements in liver health; 89% (24/27) of patients with paired liver stiffness measurements showed improved or stable liver stiffness at Week 96. The regimen was generally well-tolerated, with mild to moderate adverse events and no serious adverse events or study drug-related discontinuations.

Technical Details on Finite Treatment

Exploratory analyses evaluated the durability of viral suppression following treatment discontinuation for patients who maintained undetectable virus for at least 96 weeks. Ten patients, including seven with cirrhosis, discontinued treatment. Results showed:

  • 100% (10/10) of patients achieved SVR12.
  • 7 patients achieved SVR24 and 1 patient achieved SVR48.
  • No viral rebound or ALT flares were observed, and all 10 patients maintained stable ALT levels.

Background and Context

The combination is currently being evaluated under the ECLIPSE registrational program, which consists of three randomized, controlled trials. Vir Biotechnology reported that the pivotal Phase 3 ECLIPSE 1 trial met all study endpoints. Other trials include ECLIPSE 2, focusing on patients who failed bulevirtide therapy, and ECLIPSE 3, a head-to-head trial against bulevirtide in naïve patients.

Significance and Outlook

The potential for a finite treatment approach may shift the management of CHD from chronic suppression to a potential cure. The U.S. FDA has granted the combination Breakthrough Therapy and Fast Track designations, while the EMA has provided Priority Medicines (PRIME) and orphan drug designations. Commercialization in Europe, Australia, and New Zealand will be handled by Norgine under a December 2025 licensing agreement. A comprehensive global regulatory filing is planned for submission to the U.S. FDA in mid-2027.

[[END]]

Source: https://www.aol.com/articles/vir-biotechnology-announces-expanded-phase-214500000.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC